MESO: Mesoblast Ltd.
About
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Current Value
$10.481 Year Return
Current Value
$10.481 Year Return
Key Details
Market Cap
$1.23B
P/E Ratio
-12.17
1Y Stock Return
347.11%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
2.6
Strategies that include MESO
Stock's related to MESO
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DNUT | 49.89% | $1.84B | -15.32% | 1.30% |
| MKC | 37.47% | $20.21B | +15.19% | 2.23% |
| STOK | 36.40% | $614.95M | +197.69% | 0.00% |
| PRAX | 23.12% | $1.36B | +353.27% | 0.00% |
| BE | 22.92% | $5.43B | +85.26% | 0.00% |
| NG | 22.84% | $1.22B | -5.91% | 0.00% |
| ENTA | 22.27% | $199.60M | -5.52% | 0.00% |
| CHT | 21.90% | $29.51B | +1.71% | 3.86% |
| VYGR | 21.50% | $287.88M | -21.46% | 0.00% |
| DPZ | 21.22% | $15.19B | +19.09% | 1.31% |
| WDC | 21.19% | $22.57B | +41.20% | 0.00% |
| APPF | 21.13% | $8.30B | +16.30% | 0.00% |
| HTHT | 20.71% | $11.34B | -0.47% | 0.00% |
| REX | 20.67% | $772.08M | +19.14% | 0.00% |
| PHI | 20.26% | $4.83B | -1.80% | 7.58% |
| WYNN | 20.06% | $10.02B | +5.05% | 1.10% |
| RRR | 19.97% | $2.95B | +13.51% | 2.03% |
| JILL | 19.87% | $368.36M | -21.45% | 0.58% |
| HLNE | 19.54% | $8.12B | +108.35% | 0.95% |
| RBRK | 19.44% | $8.03B | +38.16% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HTBK | -<0.01% | $645.52M | +24.17% | 4.92% |
| UBER | <0.01% | $145.57B | +26.03% | 0.00% |
| AMBC | -<0.01% | $584.50M | -17.09% | 0.00% |
| KOS | 0.02% | $1.85B | -42.25% | 0.00% |
| CALX | -0.02% | $2.15B | -14.51% | 0.00% |
| ADNT | -0.02% | $1.65B | -41.00% | 0.00% |
| IMMP | 0.03% | $293.82M | +8.31% | 0.00% |
| CUK | 0.03% | $3.29B | +77.76% | 0.00% |
| ASC | -0.04% | $517.16M | -7.62% | 8.45% |
| CORT | -0.04% | $5.69B | +113.63% | 0.00% |
| WS | -0.05% | $2.22B | +75.00% | 1.09% |
| MHK | -0.05% | $8.56B | +61.48% | 0.00% |
| SMG | -0.05% | $4.24B | +35.01% | 3.52% |
| AVB | 0.06% | $32.63B | +34.34% | 2.94% |
| AROW | -0.06% | $546.36M | +34.05% | 4.19% |
| BROS | -0.07% | $5.67B | +74.77% | 0.00% |
| INBK | -0.07% | $350.44M | +117.95% | 0.59% |
| STRA | 0.07% | $2.33B | +6.80% | 2.53% |
| AGRO | 0.08% | $1.14B | -3.43% | 3.14% |
| FCNCA | -0.08% | $31.02B | +54.47% | 0.30% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UPS | -20.24% | $113.67B | -11.06% | 4.89% |
| IP | -14.35% | $20.09B | +78.02% | 3.20% |
| SYRS | -12.89% | $7.43M | -90.46% | 0.00% |
| BEST | -12.35% | $31.65M | +3.88% | 0.00% |
| MLKN | -11.86% | $1.62B | -9.10% | 3.20% |
| GSHD | -11.10% | $2.86B | +64.45% | 0.00% |
| ASUR | -10.78% | $233.14M | +12.13% | 0.00% |
| SATS | -9.95% | $6.59B | +129.45% | 0.00% |
| OLLI | -9.69% | $5.48B | +15.97% | 0.00% |
| BMA | -9.36% | $5.08B | +232.03% | 6.53% |
| GIS | -8.95% | $34.85B | -2.91% | 3.78% |
| CART | -8.89% | $11.00B | +73.27% | 0.00% |
| ASPS | -8.74% | $22.36M | -80.26% | 0.00% |
| ACIU | -8.70% | $325.95M | +7.92% | 0.00% |
| SUPV | -8.69% | $881.60M | +339.37% | 1.51% |
| TLPH | -8.66% | $11.41M | +9.85% | 0.00% |
| CDLX | -8.30% | $178.39M | -54.00% | 0.00% |
| INVX | -8.28% | $1.11B | -26.36% | 0.00% |
| TCTM | -8.20% | $8.10M | -42.99% | 0.00% |
| POOL | -8.18% | $13.80B | +2.93% | 1.30% |
ETF's related to MESO
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| QQA | 29.54% | $135.01M | 0% |
| RSPA | 28.11% | $273.87M | 0% |
| EFAA | 27.85% | $117.38M | 0% |
| BOXX | 22.44% | $4.43B | 0.1949% |
| EMQQ | 20.09% | $374.21M | 0.86% |
| USMF | 19.90% | $361.80M | 0.28% |
| ARKX | 19.85% | $249.95M | 0.75% |
| BUFD | 19.56% | $1.05B | 0.95% |
| VPC | 19.17% | $52.32M | 9.72% |
| XSOE | 19.12% | $1.75B | 0.32% |
| DFSE | 19.06% | $306.47M | 0.41% |
| EEM | 18.98% | $17.51B | 0.7% |
| FRDM | 18.87% | $887.11M | 0.49% |
| URA | 18.86% | $3.55B | 0.69% |
| GEM | 18.71% | $939.03M | 0.45% |
| BIZD | 18.70% | $1.25B | 13.33% |
| CHIQ | 18.58% | $229.05M | 0.65% |
| AAXJ | 18.53% | $2.51B | 0.7% |
| SCHE | 18.46% | $9.23B | 0.11% |
| GXC | 18.38% | $433.32M | 0.59% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IEI | 0.02% | $14.62B | 0.15% |
| GCOR | 0.04% | $393.53M | 0.14% |
| DFIP | -0.06% | $785.35M | 0.11% |
| GOVI | -0.06% | $1.06B | 0.15% |
| LDSF | -0.08% | $131.03M | 0.75% |
| IBDS | 0.09% | $2.63B | 0.1% |
| BSV | -0.11% | $33.43B | 0.04% |
| TIP | 0.13% | $16.12B | 0.19% |
| HTAB | 0.20% | $437.10M | 0.4% |
| WEAT | 0.23% | $120.27M | 0.28% |
| IBTE | 0.28% | $1.70B | 0.07% |
| FMHI | 0.30% | $747.15M | 0.7% |
| TBLL | -0.33% | $1.92B | 0.08% |
| NEAR | -0.34% | $2.91B | 0.25% |
| FMF | 0.34% | $244.61M | 0.95% |
| BSCR | 0.35% | $2.30B | 0.1% |
| VGIT | 0.37% | $30.89B | 0.04% |
| XONE | -0.37% | $548.88M | 0.03% |
| SCHR | 0.40% | $9.97B | 0.03% |
| SUSB | 0.49% | $959.94M | 0.12% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -14.36% | $195.31M | 0.85% |
| TAIL | -11.83% | $67.98M | 0.59% |
| BTAL | -11.14% | $388.04M | 1.43% |
| KRBN | -9.86% | $242.47M | 0.85% |
| IBDP | -8.86% | $2.11B | 0.1% |
| ULST | -8.60% | $535.47M | 0.2% |
| MUST | -7.75% | $410.00M | 0.23% |
| HDRO | -7.66% | $164.26M | 0.3% |
| UUP | -6.99% | $309.25M | 0.77% |
| KMLM | -6.74% | $353.87M | 0.9% |
| USDU | -6.60% | $201.97M | 0.5% |
| TDTT | -6.45% | $1.84B | 0.18% |
| XHLF | -6.37% | $874.27M | 0.03% |
| FTSM | -6.28% | $6.08B | 0.45% |
| STPZ | -6.26% | $483.31M | 0.2% |
| CCOR | -6.00% | $109.04M | 1.18% |
| PWZ | -5.89% | $697.36M | 0.28% |
| AGZD | -5.64% | $142.76M | 0.23% |
| BSCP | -3.94% | $4.05B | 0.1% |
| MINT | -3.57% | $11.62B | 0.35% |
News
Yahoo
Mesoblast (MESO) has released an update. Mesoblast Limited has issued 2 million unquoted warrants as part of a US$50 million convertible note facility, which the company can utilize following FDA approval. Each warrant can convert into one ordinary share or into American Depositary Receipts at a specified exchange rate. This strategic move aims to bolster Mesoblast’s financial flexibility and potential market positioning. For further insights into MESO stock, check out TipRanks’ Stock Analysis p
Yahoo
The Australian market has shown resilience with the ASX200 gaining 1.1% and all sectors marking positive territory, led by IT and Materials. In this buoyant environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong management confidence and potential for substantial earnings growth, making them noteworthy in a flourishing market landscape.
Yahoo
As the Australian market experiences a modest uptick with the ASX200 rising around 1% to 8,210 points, investors are closely monitoring the ongoing US election and its potential impact on global markets. In this environment of cautious optimism, identifying high growth tech stocks requires careful consideration of factors such as innovation potential, market positioning, and adaptability in dynamic sectors like technology.
Yahoo
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2024. Mesoblast Chief Executive Silviu Itescu said: “We have had an extremely busy and productive quarter starting right from the outset with the filing of our Biologics License Application (BLA) with the United States Food and Drug Administration
Yahoo
With the business potentially at an important milestone, we thought we'd take a closer look at Mesoblast Limited's...
Yahoo
Mesoblast (MESO) has released an update. Mesoblast Limited is making strides in advancing its late-stage pipeline of innovative cellular medicines targeting serious inflammatory diseases. The company is preparing to launch Ryoncil®, a treatment for steroid-refractory acute GvHD in children, pending FDA approval, and has secured $50 million to support commercialization efforts. Additionally, Mesoblast is progressing with a Phase 3 trial for rexlemestrocel-L to address chronic low back pain, highl
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.